Dicerna Announces Proof of Concept for DCR-PHXC in the Treatment of Primary Hyperoxaluria
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Dicerna Pharmaceuticals (DRNA) PT Raised to $20 at SunTrust Robinson Humphrey
September 5, 2018 9:48 AM EDTSunTrust Robinson Humphrey analyst Edward Nash raised the price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $20.00 (from $15.00) while maintaining a Buy rating after the company reported PoC data from the ongoing Phase I PHYOX study in primary hyperoxaluria I and... More
